News
     
Featured Releases
  •  
    August 27, 2013
    Congenia Announces Enrollment of First Healthy Volunteer in Phase 1 Clinical Trial of GNX-5086
    download
    (67,9KB)
  •  
    July 30, 2013
    EryDel SpA Announces FDA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia
    download
    (50,4KB)
  •  
    July 7, 2013
    EryDel Spa Completes €15 Million Series B financing
    download
    (603KB)
  •  
    June 24, 2013
    Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
    download
    (7,93KB)
  •  
    April 30, 2013
    Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis
    download
    (11,3KB)
  •  
    April 29, 2013
    EryDel announces US IND approval for EryDex
    download
    (86,6KB)
  •  
    November 8, 2012
    Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at AASLD's Liver Meeting
    download
    (58,0KB)
  •  
    October 11, 2012
    Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
    download
    (62,5KB)
  •  
    August 9, 2012
    Intercept Pharmaceuticals Closes $30 Million Series C Financing OrbiMed’s Jonathan Silverstein and Klaus Veitinger Join Board of Directors
    download
    (38,5KB)
  •  
    August 9, 2011
    Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes
    download
    (24,4KB)
  •  
    March 30, 2011
    Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
    download
    (114KB)
  •  
    July 28, 2010
    Intercept Pharmaceuticals to Collaborate with NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
    download
    (20,5KB)
  •  
    Jul 6, 2010
    Atlante Ventures acquires interest in Tethis (Genextra Group)
    download
    (136KB)
  •  
    April 13, 2010
    Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL
    download
    (66,8KB)
  •  
    Jan 25, 2010
    Intercept Pharmaceuticals Raises $25 Million Series B Financing
    download
    (89,2KB)
  •  
    Jan 25, 2010
    Genextra further invests $25 million series B financing in Intercept Pharmaceuticals
    download
    (136KB)
  •  
    Dec 14, 2009
    Genextra S.p.A. raises over € 36 million in equity financing
    download
    (16,2KB)
  •  
    Oct 27, 2009
    Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
    download
    (16,5KB)
  •  
    Oct 2, 2009
    Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
    download
    (13,9KB)
  •  
    Sept 2, 2009
    Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity ...
    download
    (36,0KB)
  •  
    Jan 14, 2009
    Tethis establishes a collaborative agreement with Cogentech (Consortium for Genomic Technologies, Milan), to validate a novel platform for phosphoproteomic analysis by Mass spectrometry.
    download
    (71KB)
  •  
    Dec 12, 2008
    Tethis establishes a collaborative project with European Institute of Oncology, Milan (EIO) to validate its ImmunoCell-Array technology for the analysis of novel putative biomarkers in cancer
    download
    (70KB)
  •  
    Jul 29, 2008
    Genextra completes $25 million financing to support completion of Intercept Pharmaceuticals’ INT-747
    download
    (30,3KB)
  •  
    Nov 21, 2008
    Tethis presents its new system for the deposition of functional coatings on microfabricated devices
    download
    (55KB)
  •  
    Oct 28, 2008
    DAC s.r.l. Initiates Phase I/IIa Clinical Trial For DAC-0060 To Treat Nonmelanoma Skin Cancers
    download
    (51,7KB)
  •  
    Aug 7, 2008
    Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling, Intercept Pharmaceuticals is Advancing Bile Acid-Derived Small Molecules with Potential Applications in Treating Metabolic Diseases ...
    download
    (820KB)
  •  
    Jul 29, 2008
    Intercept Pharmaceuticals Raises $25 Million, Funding Will Support Completion of INT-747 Phase II Clinical Trials and Acceleration of Pipeline Development, Dr. Kenneth D. Noonan Appointed Chairman ...
    download
    (32,2KB)
  •  
    May 16, 2006
    Intercept Pharmaceuticals closes $41 million equity financing
    download
    (16,3KB)
  •  
    Sept 28, 2005
    Genextra entra nel settore delle nanotecnologie e acquisisce il controllo di Tethis
    download
    (52KB)